SG11201810853UA - Anti-tnfrsf25 antibodies - Google Patents
Anti-tnfrsf25 antibodiesInfo
- Publication number
- SG11201810853UA SG11201810853UA SG11201810853UA SG11201810853UA SG11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- pct
- durham
- english
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241001598984 Bromius obscurus Species 0.000 abstract 1
- 241000272194 Ciconiiformes Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348009P | 2016-06-09 | 2016-06-09 | |
| PCT/US2017/036817 WO2017214547A1 (en) | 2016-06-09 | 2017-06-09 | Anti-tnfrsf25 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810853UA true SG11201810853UA (en) | 2019-01-30 |
Family
ID=59078259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810853UA SG11201810853UA (en) | 2016-06-09 | 2017-06-09 | Anti-tnfrsf25 antibodies |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10005843B2 (ko) |
| EP (1) | EP3468998B1 (ko) |
| JP (1) | JP6961625B2 (ko) |
| KR (1) | KR102423942B1 (ko) |
| CN (1) | CN109219620B (ko) |
| AU (1) | AU2017278192A1 (ko) |
| BR (1) | BR112018075222A2 (ko) |
| CA (1) | CA3026652A1 (ko) |
| DK (1) | DK3468998T3 (ko) |
| IL (1) | IL263406B2 (ko) |
| MX (1) | MX2018014716A (ko) |
| RU (1) | RU2746314C2 (ko) |
| SG (1) | SG11201810853UA (ko) |
| WO (1) | WO2017214547A1 (ko) |
| ZA (1) | ZA201808317B (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016215175B2 (en) * | 2015-02-06 | 2021-09-16 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| WO2022212668A1 (en) * | 2021-03-31 | 2022-10-06 | Heat Biologics, Inc. | Methods and compositions related to tnfrsf25/dr3 agonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3854306B2 (ja) | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| NZ249677A (en) | 1992-02-19 | 1996-08-27 | Schering Corp | Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| WO2005018571A2 (en) | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| US7612179B2 (en) | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| AU2006284922B2 (en) * | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| PL2066351T3 (pl) | 2006-10-02 | 2016-02-29 | Squibb & Sons Llc | Przeciwciała ludzkie wiążące CXCR4 i ich wykorzystanie |
| FR2907341B1 (fr) | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| ES2586837T3 (es) | 2009-08-03 | 2016-10-19 | University Of Miami | Método para la expansión in vivo de linfocitos T reguladores |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
| RU2551235C2 (ru) * | 2013-08-26 | 2015-05-20 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| CN103592439B (zh) * | 2013-09-03 | 2015-10-21 | 天津亿美诺生物科技有限公司 | 人尿路上皮癌特异性抗体及其应用 |
| WO2016081455A1 (en) | 2014-11-17 | 2016-05-26 | Pelican Therapeutics, Inc. | Human tnfrsf25 antibody |
-
2017
- 2017-06-09 EP EP17731434.1A patent/EP3468998B1/en active Active
- 2017-06-09 JP JP2018563618A patent/JP6961625B2/ja active Active
- 2017-06-09 SG SG11201810853UA patent/SG11201810853UA/en unknown
- 2017-06-09 MX MX2018014716A patent/MX2018014716A/es unknown
- 2017-06-09 CA CA3026652A patent/CA3026652A1/en active Pending
- 2017-06-09 RU RU2018143977A patent/RU2746314C2/ru active
- 2017-06-09 IL IL263406A patent/IL263406B2/en unknown
- 2017-06-09 BR BR112018075222-3A patent/BR112018075222A2/pt unknown
- 2017-06-09 CN CN201780034593.5A patent/CN109219620B/zh active Active
- 2017-06-09 AU AU2017278192A patent/AU2017278192A1/en not_active Abandoned
- 2017-06-09 US US15/618,993 patent/US10005843B2/en active Active
- 2017-06-09 WO PCT/US2017/036817 patent/WO2017214547A1/en unknown
- 2017-06-09 DK DK17731434.1T patent/DK3468998T3/da active
- 2017-06-09 KR KR1020187035804A patent/KR102423942B1/ko active IP Right Grant
-
2018
- 2018-04-27 US US15/964,775 patent/US10683359B2/en active Active
- 2018-12-10 ZA ZA2018/08317A patent/ZA201808317B/en unknown
-
2020
- 2020-05-14 US US16/874,290 patent/US20210017287A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL263406A (en) | 2018-12-31 |
| EP3468998B1 (en) | 2021-12-01 |
| US10683359B2 (en) | 2020-06-16 |
| AU2017278192A1 (en) | 2018-12-13 |
| JP6961625B2 (ja) | 2021-11-10 |
| DK3468998T3 (en) | 2022-03-07 |
| EP3468998A1 (en) | 2019-04-17 |
| RU2018143977A (ru) | 2020-07-09 |
| US20210017287A1 (en) | 2021-01-21 |
| KR20190015716A (ko) | 2019-02-14 |
| BR112018075222A2 (pt) | 2019-03-19 |
| WO2017214547A1 (en) | 2017-12-14 |
| US20170355773A1 (en) | 2017-12-14 |
| US20180312599A1 (en) | 2018-11-01 |
| CA3026652A1 (en) | 2017-12-14 |
| JP2019526528A (ja) | 2019-09-19 |
| IL263406B1 (en) | 2023-05-01 |
| ZA201808317B (en) | 2019-08-28 |
| IL263406B2 (en) | 2023-09-01 |
| CN109219620B (zh) | 2023-01-31 |
| KR102423942B1 (ko) | 2022-07-22 |
| RU2018143977A3 (ko) | 2020-10-05 |
| CN109219620A (zh) | 2019-01-15 |
| US10005843B2 (en) | 2018-06-26 |
| MX2018014716A (es) | 2019-03-11 |
| RU2746314C2 (ru) | 2021-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408261UA (en) | Syringe | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau |